Fibrosis Discovery Performance Unit (DPU), Respiratory Therapy Area Unit (TAU), GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Fibrosis Discovery Performance Unit (DPU), Respiratory Therapy Area Unit (TAU), GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
J Pharmacol Exp Ther. 2021 Feb;376(2):273-280. doi: 10.1124/jpet.120.000379. Epub 2020 Dec 14.
The arginyl-glycinyl-aspartic acid (RGD) integrin alpha-v beta-6 (v6) has been identified as playing a key role in the activation of transforming growth factor- (TGF) that is hypothesized to be pivotal in the development of fibrosis and other diseases. In this study, v6 small molecule inhibitors were characterized in a range of in vitro systems to determine affinity, kinetics, and duration of TGF inhibition. High v6 binding affinity was shown to be correlated with slow dissociation kinetics. Compound (high v6 affinity, slow dissociation) and SC-68448 (low v6 affinity, fast dissociation) induced concentration- and time-dependent internalization of v6 in normal human bronchial epithelial (NHBE) cells. After washout, the v6 cell surface repopulation was faster for SC-68448 compared with compound In addition, v6-dependent release of active TGF from NHBE cells was inhibited by compound and SC-68448. After washout of SC-68448, release of active TGF was restored, whereas after washout of compound the inhibition of TGF activation was maintained and only reversible in the presence of a lysosomal inhibitor (chloroquine). However, SC-68448 was able to reduce total levels of v6 in NHBE cells if present continuously. These observations suggest v6 can be degraded after high affinity RGD binding that sorts the integrin for lysosomal degradation after internalization, likely due to sustained engagement as a result of slow dissociation kinetics. In addition, the v6 integrin can also be downregulated after sustained engagement of the RGD binding site with low affinity ligands that do not sort the integrin for immediate lysosomal degradation. SIGNIFICANCE STATEMENT: The fate of RGD integrin after ligand binding has not been widely investigated. Using the αvβ6 integrin as a case study, we have demonstrated that RGD-induced downregulation of αvβ6 is both affinity and time dependent. High affinity ligands induced downregulation via lysosomal degradation, likely due to slow dissociation, whereas sustained low affinity ligand engagement was only able to decrease αvβ6 expression over longer periods of time. Our study provides a potential unique mechanism for obtaining duration of action for drugs targeting integrins.
精氨酸-甘氨酸-天冬氨酸(RGD)整合素αvβ6(v6)已被确定在转化生长因子-(TGF)的激活中发挥关键作用,该因子被假设在纤维化和其他疾病的发展中起关键作用。在这项研究中,v6 小分子抑制剂在一系列体外系统中进行了表征,以确定亲和力、动力学和 TGF 抑制的持续时间。高 v6 结合亲和力与缓慢的解离动力学相关。化合物 (高 v6 亲和力,缓慢解离)和 SC-68448(低 v6 亲和力,快速解离)诱导正常人类支气管上皮(NHBE)细胞中 v6 的浓度和时间依赖性内化。洗出后,与化合物 相比,SC-68448 使 v6 更快地重新填充 NHBE 细胞的表面。此外,化合物 和 SC-68448 抑制 NHBE 细胞中活性 TGF 的 v6 依赖性释放。洗出 SC-68448 后,释放的活性 TGF 得到恢复,而洗出化合物 后,TGF 激活的抑制作用得以维持,只有在溶酶体抑制剂(氯喹)存在时才可逆。然而,如果持续存在,SC-68448 能够降低 NHBE 细胞中的总 v6 水平。这些观察结果表明,在高亲和力 RGD 结合后,v6 可以被降解,这将整合素分选到溶酶体降解,可能是由于持续结合导致缓慢解离动力学。此外,在低亲和力配体持续结合 RGD 结合位点后,v6 整合素也可以下调,而这些低亲和力配体不会将整合素分选到立即进行溶酶体降解。意义声明:配体结合后 RGD 整合素的命运尚未得到广泛研究。使用 αvβ6 整合素作为案例研究,我们已经证明,RGD 诱导的 αvβ6 下调既与亲和力有关,也与时间有关。高亲和力配体通过溶酶体降解诱导下调,可能是由于缓慢解离,而持续的低亲和力配体结合仅能在较长时间内降低 αvβ6 表达。我们的研究为靶向整合素的药物获得作用持续时间提供了一种潜在的独特机制。